Navigation Links
Progen Announces PI-88 Phase 2 Lung Cancer Results
Date:9/24/2007

BRISBANE, Sept. 24 /PRNewswire-FirstCall/ -- Progen Pharmaceuticals Limited (ASX: PGL; Nasdaq: PGLA) today announced that the Phase 2 trial administering 250mg of PI-88 in combination with the chemotherapeutic agent docetaxel to patients with advanced non small cell lung cancer did not meet its primary endpoint of significantly improving the progression-free rate at six months compared to docetaxel alone. The trial also did not meet its secondary endpoints of improvement in time to progression, response rate, overall survival and quality of life measures.

The overall data from this trial suggests that no further investigation of PI-88 in combination with docetaxel in patients with non small cell lung cancer that have failed platinum based first line therapies is warranted. However, nine patients in the study switched to PI-88 after experiencing toxicity or disease progression with docetaxel monotherapy. The data for this patient group suggests a potential survival benefit that Progen intends to investigate further with, amongst others, the clinicians involved in this study.

"We are disappointed, first and foremost, for the patients with non small cell lung cancer that have disease progression following platinum based chemotherapy as treatment options are limited," said Justus Homburg, Progen's Chief Executive Officer. "The outcome of this study has no impact on our Phase 3 registration strategy for patients with post-resection liver cancer which we announced today has been granted fast-track status designation by the U.S. FDA."

"It is quite common for new drugs to show benefit in one patient group but limited benefit in another. To date, PI-88 has shown evidence of benefit in patients with melanoma, multiple myeloma and post-resection liver cancer. In particular, PI-88 may be more active for tumors that are at an earlier disease stage, such as has been demonstrated in the PI-88 Phase 2 primary liver cancer trial" added Homburg. "In that trial, patients were at high risk of disease recurrence but had no demonstrable disease present at the time of starting therapy with PI-88" he said. "We remain committed to the ongoing development of PI-88, especially given the exciting Phase 2 data seen in the primary liver cancer trial."

About Progen:

Progen Pharmaceuticals Limited is an Australian-based globally focused biotechnology company committed to the discovery, development and commercialization of small molecule therapeutics primarily for the treatment of cancer.

Progen Information:

Justus Homburg

Progen Pharmaceuticals Limited

T: +61 7 3842 3333

E: justush@progen-pharma.com

Sarah Meibusch

Progen Pharmaceuticals Limited

T: +61 7 3842 3333

E: sarahm@progen-pharma.com

Media and Investor Relations Australia:

Rebecca Piercy

Buchan Consulting

T: +61 2 9237 2800 / +61 422 916 422

E: rpiercy@bcg.com.au

Rebecca Wilson

Buchan Consulting

T: +61 417 382 391

E: rwilson@bcg.com.au

Media Relations USA:

Robert D. Stanislaro

Financial Dynamics

T: 212-850-5657

E: robert.stanislaro@fd.com

Investor Relations USA:

Evan Smith

Financial Dynamics

T: 212-850-5606

E: evan.smith@fd.com


'/>"/>
SOURCE Progen Pharmaceuticals Limited
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Progenics and Wyeth Announce Positive Results from Three-Month Clinical-Extension Study of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness
2. Progenics Announces Positive Results in Clinical Trial of Novel HIV Therapy
3. Progens Phase 2 Liver Cancer Trial Exceeds Efficacy Objective
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Sygnis Pharma AG announces date for presentation of clinical results
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... 19, 2017 James ... & Haematology, 2016;12(Suppl 2):3-8; http://www.touchoncology.com/articles/optimising-clinical-outcomes-gastrointestinal-cancers-through-inhibiting-angiogenesis-and ... ... Published recently in a supplement to European ... touchONCOLOGY, an article by James Gilbart ...
(Date:1/19/2017)... LEXINGTON, Massachusetts , January 19, 2017 ... SHPG ) announced that the U.S. Food and Drug ... resubmission of a New Drug Application (NDA) for SHP465, ... being evaluated as a potential once-daily treatment for Attention-Deficit/Hyperactivity ... decision on or around June 20, 2017, the designated ...
(Date:1/19/2017)... LONDON , January 19, 2017 ... New Therapeutic Option to Address Motor Symptoms and ... ...      (Logo: http://photos.prnewswire.com/prnh/20151014/276718LOGO) ... Fabrizio Stocchi , European Neurological Review,2016;11(Suppl. 2): 2-15, ...
Breaking Medicine Technology:
(Date:1/20/2017)... ... January 20, 2017 , ... ... to enhance people’s everyday lives, recently attended the January ECRM Trade Show in ... Science is known for its large range of supplements that keep the body ...
(Date:1/20/2017)... ... January 20, 2017 , ... Michael and Betsy Brauser celebrated 5 years of ... the clinical trial has been life-saving as she has been on the trial ... Brauser was diagnosed with ovarian cancer in 2009. She underwent standard chemotherapy but a ...
(Date:1/20/2017)... ... 20, 2017 , ... Vitamin Well has launched two new ... have been produced in collaboration with Zlatan Ibrahimovic and have been developed to ... a successful launch in Sweden last year, the next generation sports drinks VW+001 ...
(Date:1/20/2017)... ... January 20, 2017 , ... “The Angel”: a heartwarming and earnest ... for each of his children. “The Angel” is the creation of published author, Marjorie ... York City, and impassioned writer. , When asked of her new book, Marjorie says, ...
(Date:1/20/2017)... ... ... You”: a fine examination of how God handles sin, including how to let go ... Miller, who, for over ten long years has been waiting to release this powerful insight ... he has been serving the Lord for over twenty years, and he has been preaching ...
Breaking Medicine News(10 mins):